Efficacy and Safety of Insuman Basal/Comb/Rapid in Patients With Type 2 Diabetes

Inclusion criteria : * T2DM patients uncontrolled by maximum tolerated dose of 1-2 OADs * Males and Female \> 18 years * HbA1c \> 7.5% * Patients with abilities of self-monitoring of Diabetes, managing of patient's diary, ability to obtain education in Diabetes School, completion of Questionnaire * It is expected that the patient will remain on a stable dose of OADs within 6 months of treatment Exclusion criteria : * Type 1 diabetes * Current temporary insulin therapy (gestational diabetes, pancreas cancer, surgery, clinical trial) * Any clinically significant acute major organ or systemic diseases making interpretation of the evaluation results difficult * Patient planning a pregnancy now or in the next 6 months * The patient is participating in another clinical study now or in the last 28 days prior to Visit 1 * The patient is a drug user (currently or in the past) The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.